| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.13 | 9e-05 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.2 | 0.0001 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.0002 |